title: The effects of hepatitis C virus core protein on the expression of miR-122 in vitro.
abstract: BACKGROUND
  Hepatitis C virus (HCV) is one of the major pathogens of liver diseases. Some studies have previously reported that miR-122 can stimulate replication or translation of HCV. However, the effects of HCV infection on miR-122 expression are not clear. The aim of this study was to investigate the effects of HCV core protein on the expression of miR-122 in a cell culture model.
  
  
  RESULTS
  The miR-122 levels in Huh7.5.1 cells infected with HCV for different days or different HCV abundance were measured by real-time PCR. Significant decrease of miR-122 expression was found at late stage of infection and in the high-abundance group. Huh7.5.1 cells transfected with plasmid pEGFP-core or pEGFP were used to detect the effects of HCV core protein on miR-122 expression, the results showed that core protein could down-regulate the miR-122 expression level in a time- and dose- dependent manner, and reduced the susceptibility of Huh7.5.1 cell to HCV.
  
  
  CONCLUSIONS
  Down-regulating miR-122 expression by HCV core protein may give a new insight into the interaction between HCV and miR-122 and chronic HCV infection.
authors.affiliation: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Institute of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Sujuan
authors.initials: S
authors.lastname: Li
authors.forename: Xiaokang
authors.initials: X
authors.lastname: Xing
authors.forename: Qiao
authors.initials: Q
authors.lastname: Yang
authors.forename: Hangdi
authors.initials: H
authors.lastname: Xu
authors.forename: Jiliang
authors.initials: J
authors.lastname: He
authors.forename: Zhi
authors.initials: Z
authors.lastname: Chen
authors.forename: Haihong
authors.initials: H
authors.lastname: Zhu
mesh_terms: D002460:Cell Line; D015870:Gene Expression; D020869:Gene Expression Profiling; D016174:Hepacivirus / Q000472:pathogenicity*; D022781:Hepatocytes / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis*; D060888:Real-Time Polymerase Chain Reaction; D014758:Viral Core Proteins / Q000378:metabolism*
chemical_list: C531907:MIRN122 microRNA, human; D035683:MicroRNAs; D014758:Viral Core Proteins; C069130:nucleocapsid protein, Hepatitis C virus
references.citation: N Engl J Med. 2001 Jul 5;345(1):41-52
references.pmid: 11439948
references.citation: Hepatology. 2011 Apr;53(4):1090-9
references.pmid: 21480315
references.citation: N Engl J Med. 2011 Jun 23;364(25):2405-16
references.pmid: 21696307
references.citation: Science. 2005 Sep 2;309(5740):1577-81
references.pmid: 16141076
references.citation: N Engl J Med. 2011 Jun 23;364(25):2417-28
references.pmid: 21696308
references.citation: RNA Biol. 2004 Jul;1(2):106-13
references.pmid: 17179747
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: J Interferon Cytokine Res. 2004 Jul;24(7):391-402
references.pmid: 15296650
references.citation: Virol J. 2005 Aug 22;2:70
references.pmid: 16115320
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17717-22
references.pmid: 16301520
references.citation: Liver Int. 2011 Apr;31(4):474-84
references.pmid: 21199296
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12884-9
references.pmid: 17616579
references.citation: JAMA. 2003 May 14;289(18):2413-7
references.pmid: 12746366
references.citation: Gastroenterology. 2007 Oct;133(4):1166-74
references.pmid: 17919492
references.citation: Virol J. 2007 Mar 13;4:29
references.pmid: 17355620
references.citation: PLoS One. 2011;6(8):e23937
references.pmid: 21886843
references.citation: Med Hypotheses. 2004;63(3):515-23
references.pmid: 15288380
references.citation: Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2992-7
references.pmid: 15710891
references.citation: Science. 1999 Jul 2;285(5424):107-10
references.pmid: 10390359
references.citation: Nat Med. 2009 Jan;15(1):31-3
references.pmid: 19122656
references.citation: N Engl J Med. 2011 Mar 31;364(13):1195-206
references.pmid: 21449783
references.citation: J Gen Virol. 1999 Apr;80 ( Pt 4):879-886
references.pmid: 10211956
references.citation: Ann Intern Med. 2004 Mar 2;140(5):346-55
references.pmid: 14996676
references.citation: Virol J. 2005 Feb 11;2:10
references.pmid: 15707489
references.citation: J Med Virol. 2004 Aug;73(4):536-47
references.pmid: 15221897
references.citation: N Engl J Med. 2011 Mar 31;364(13):1207-17
references.pmid: 21449784
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Lab Invest. 2010 Dec;90(12):1727-36
references.pmid: 20625373
references.citation: Nat Rev Immunol. 2005 Mar;5(3):215-29
references.pmid: 15738952
references.citation: EMBO J. 2008 Dec 17;27(24):3300-10
references.pmid: 19020517